Marshall Wace
KRYS icon

Marshall Wace’s Krystal Biotech KRYS Stock Holding History

Marshall Wace’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-68,343
Closed -$17.7M – 3469
2026
Q1 		$17.7M Sell
68,343
-115,411
-63% -$30.7M 0.02% 751
2025
Q4 		$45.3M Buy
183,754
+54,794
+42% +$11.5M 0.04% 364
2025
Q3 		$22.8M Buy
128,960
+16,578
+15% +$2.48M 0.02% 596
2025
Q2 		$15.4M Buy
112,382
+95,158
+552% +$14M 0.02% 678
2025
Q1 		$3.11M Buy
17,224
+6,893
+67% +$1.16M ﹤0.01% 1271
2024
Q4 		$1.62M Buy
+10,331
New +$1.83M ﹤0.01% 1528
2024
Q2 		– Sell
-5,600
Closed -$996K – 2754
2024
Q1 		$996K Sell
5,600
-65,301
-92% -$9.07M ﹤0.01% 1651
2023
Q4 		$8.8M Buy
70,901
+61,373
+644% +$6.81M 0.01% 725
2023
Q3 		$1.11M Buy
+9,528
New +$1.16M ﹤0.01% 1464
2023
Q2 		– Sell
-8,571
Closed -$686K – 2727
2023
Q1 		$686K Sell
8,571
-3,629
-30% -$285K ﹤0.01% 1971
2022
Q4 		$966K Buy
+12,200
New +$906K ﹤0.01% 2107
2022
Q1 		– Sell
-108,511
Closed -$7.59M – 3694
2021
Q4 		$7.59M Buy
108,511
+82,856
+323% +$4.82M 0.01% 1068
2021
Q3 		$1.34M Buy
+25,655
New +$1.52M 0.01% 1818
2021
Q2 		– Sell
-29,836
Closed -$2.3M – 2864
2021
Q1 		$2.3M Buy
29,836
+22,409
+302% +$1.63M 0.01% 1255
2020
Q4 		$446K Buy
+7,427
New +$371K ﹤0.01% 1501

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace's KRYS Position: Q2 2026 in Review

Marshall Wace sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 68,343 shares — an estimated $17.7M sold.

Marshall Wace first reported a position in KRYS in Q4 2020 and held it in 15 quarters. The position peaked at $45.3M in Q4 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Marshall Wace reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 68,343 Krystal Biotech shares in Q2 2026, an estimated $17.7M.
  • Marshall Wace first reported a position in Krystal Biotech in Q4 2020 and held it in 15 quarters.
  • Marshall Wace's Krystal Biotech position peaked at $45.3M in Q4 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.